• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Capstone Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    4/1/25 4:15:12 PM ET
    $CAPS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CAPS alert in real time by email
    false 0000887151 0000887151 2025-04-01 2025-04-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): April 1, 2025

     

    CAPSTONE HOLDING CORP.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-33560   86-0585310

    (State or other jurisdiction

    of incorporation)

      (Commission File Number)  

    (I.R.S. Employer

    Identification No.)

     

    5141 W. 122nd Street

    Alsip, IL 60803

    (Address of principal executive offices)

     

    Registrant’s telephone number, including area code: (708) 371-0660

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0005 par value   CAPS   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 2.02 Results of Operations and Financial Condition

     

    On April 1, 2025, Capstone Holding Corp. (the “Company”) announced its financial results for the fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 7.01. Regulation FD Disclosure.

     

    The Company also prepared an investor presentation containing certain information and financial highlights about the Company. A copy of the presentation materials is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

     

    The information set forth in Item 2.02 and Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language contained in such filing, except as expressly set forth by specific reference in such a filing.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit
    Number
      Exhibits
    99.1   Press Release of Capstone Holding Corp. entitled “Capstone Targets $100M Run Rate Increases Q4 Revenue and Executes Strategic Brand Expansion”
    99.2   Capstone Holding Corp. Investor Presentation (March 2025)
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: April 1, 2025 Capstone Holding Corp.
         
      By: /s/ Matthew E. Lipman
      Name:  Matthew E. Lipman
      Title: Chief Executive Officer

     

    2

     

    Get the next $CAPS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Schultz Edward Christopher

      3 - Capstone Holding Corp. (0000887151) (Issuer)

      4/22/25 3:55:58 PM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Lipman Matthew E. claimed ownership of 2,650,436 shares (SEC Form 3)

      3 - Capstone Holding Corp. (0000887151) (Issuer)

      4/22/25 3:53:49 PM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Holliman John M Iii claimed ownership of 1,095 shares (SEC Form 3)

      3 - Capstone Holding Corp. (0000887151) (Issuer)

      4/14/25 7:04:52 PM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CAPS
    SEC Filings

    See more
    • SEC Form 424B4 filed by Capstone Holding Corp.

      424B4 - Capstone Holding Corp. (0000887151) (Filer)

      6/12/25 1:58:16 PM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Capstone Holding Corp.

      EFFECT - Capstone Holding Corp. (0000887151) (Filer)

      6/12/25 12:15:12 AM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Capstone Holding Corp.

      S-1/A - Capstone Holding Corp. (0000887151) (Filer)

      6/9/25 5:00:47 PM ET
      $CAPS
      Biotechnology: Pharmaceutical Preparations
      Health Care